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Abst rac t
Background and purpose: The results of a few studies sug-
gest that magnetic resonance spectroscopy of the brain could
allow detection of minimal hepatic encephalopathy. The goal
of this study was to assess the ability of magnetic resonance
spectroscopy to differentiate between cirrhotic patients with
and without minimal hepatic encephalopathy.
Material and methods: Localized magnetic resonance spec-
troscopy was performed in the basal ganglia, occipital gray
matter and frontal white matter in 46 patients with liver cir-
rhosis without overt encephalopathy and in 45 controls. Neu-
rological and neuropsychological examination was performed
in each participant.
Results: The patients with liver cirrhosis had a decreased ratio
of myoinositol to creatine in occipital gray matter and frontal
white matter (mean: 0.17 ± 0.05 vs. 0.20 ± 0.04, p = 0.01
and 0.15 ± 0.05 vs. 0.19 ± 0.04, p < 0.01, respectively) and
a decreased ratio of choline to creatine in occipital gray mat-
ter (mean: 0.32 ± 0.07 vs. 0.36 ± 0.08, p = 0.03). Minimal
hepatic encephalopathy was diagnosed in 7 patients. Metabo-
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Wstêp i cel pracy: Wyniki pojedynczych badañ sugeruj¹, ¿e
spektroskopia rezonansu magnetycznego mózgu mo¿e byæ
pomocna w wykrywaniu minimalnej encefalopatii w¹trobo-
wej. Celem tego badania by³a ocena przydatnoœci spektro-
skopii rezonansu magnetycznego w odró¿nianiu pacjentów
z marskoœci¹ w¹troby z minimaln¹ encefalopati¹ w¹trobow¹
od pacjentów bez tej encefalopatii. 
Materia³ i metody: Badanie spektroskopii rezonansu magne-
tycznego mózgu przeprowadzono u 46 pacjentów z marsko-
œci¹ w¹troby bez jawnej encefalopatii i u 45 osób z grupy kon-
trolnej. Rejestracji widm dokonano z trzech obszarów mózgu:
zwojów podstawy, istoty szarej p³ata potylicznego i istoty bia³ej
p³ata czo³owego. U wszystkich badanych osób przeprowa-
dzono badanie neurologiczne i neuropsychologiczne.
Wyniki: U pacjentów z marskoœci¹ w¹troby stwierdzono
obni¿enie stosunku mioinozytolu do kreatyny w zakresie p³ata
potylicznego i czo³owego (œrednie odpowiednio 0,17 ± 0,05
vs 0,20 ± 0,04, p = 0,01 oraz 0,15 ± 0,05 vs 0,19 ± 0,04, 
p < 0,01) oraz zmniejszenie stosunku choliny do kreatyny
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Introduction
Proton magnetic resonance spectroscopy (MRS)
allows in vivo measurement of different metabolites in
the brain. MRS studies showed a decrease in the ratio
of choline (Cho) to creatine (Cr) and myoinositol (Ins)
to Cr and an increase in the ratio of glutamine/gluta-
mate (Glx) to Cr in brains of patients with hepatic en -
cephalopathy [1,2]. 
Minimal hepatic encephalopathy (MHE) is a sub-
tle cognitive impairment commonly seen in patients with
liver cirrhosis [3,4]. Identification of patients with
MHE could be clinically important, because this group
of patients has increased risk of overt encephalopathy
and death [5,6]. Moreover, patients with MHE have
reduced quality of life and deterioration in daily func-
tioning including driving abilities [7]. The diagnosis
of MHE is mainly based on performance of psycho-
metric and/or neurophysiological tests. The results
of neuropsychological and some neurophysiological tests
could be, however, influenced by different factors includ-
ing age, education, mood, degree of patient cooperation,
etc. Taking into account these limitations, new methods
allowing more objective identification of patients who
are at risk of encephalopathy are needed.    
Several studies have shown that patients with MHE
have a decreased ratio of Ins/Cr and Cho/Cr and an
increased ratio of Glx/Cr compared to controls [8-13].
Moreover, it was suggested that MRS allows accurate
diagnosis of MHE [11,14]. In one study, MRS was
able to differentiate patients with MHE from healthy
controls with 100% accuracy when Ins depletion in the
frontal and occipital lobe was used as a discriminating
factor [11]. It should be noted that these studies com-
pared patients with MHE only with healthy subjects.
Therefore, it remains unclear whether MRS is able to
differentiate patients with MHE from patients with liv-
er cirrhosis without cognitive impairment. 
The goal of our study was to assess the ability of
MRS to differentiate between patients with liver cir-
rhosis with and without MHE. 
Material and methods
The patients participating in this study were recruit-
ed from the patients with liver cirrhosis admitted from
October 2008 to March 2011 to the outpatient clinic in
the Department of Gastroenterology, Hepatology and
Infectious Diseases, University Hospital in Krakow.
The diagnosis of cirrhosis was based on clinical and bio-
chemical data, results of ultrasound examination of the
abdomen and, in selected cases, liver biopsy.
The exclusion criteria were: (1) overt hepatic ence -
phalopathy or history of encephalopathy in the past; 
(2) history of psychiatric or neurological disorders; 
(3) history of recent use of drugs affecting psychome -
tric performance (for example benzodiazepines, psycho -
tropic drugs, etc.); (4) presence of structural changes
on magnetic resonance imaging (MRI) which could
interfere with results of spectroscopy or results of psy-
chometric tests; (5) known central nervous system dis-
eases, diabetes mellitus, severe cardiac and renal diseas -
es; (6) active alcohol and drug abuse.
lite ratios did not differ significantly between patients with
and without minimal hepatic encephalopathy. Metabolite
ratios did not differ significantly between patients with Child-
Pugh A and those with Child-Pugh B.
Conclusions: Magnetic resonance spectroscopy does not allow
accurate diagnosis of minimal hepatic encephalopathy. A sim-
i lar profile of metabolites in the brain is observed in cirrho -
tic patients without cognitive impairment. 
Key words: magnetic resonance spectroscopy, minimal hepa -
tic encephalopathy, liver cirrhosis, neuropsychological assess-
ment.
w p³acie potylicznym (œrednia: 0,32 ± 0,07 vs 0,36 ± 0,08, 
p = 0,03) w porównaniu z grup¹ kontroln¹. Minimaln¹ ence-
falopatiê w¹trobow¹ rozpoznano u 7 pacjentów. Stosunek meta-
bolitów nie ró¿ni³ siê istotnie u pacjentów z minimaln¹ encefa-
lopati¹ w¹trobow¹ i bez niej. Nie stwierdzono tak¿e ró¿nicy
w stê¿eniu metabolitów u pacjentów z niewydolnoœci¹ w¹troby
zakwalifikowanych do kategorii A w skali Child-Pugh w po -
równaniu z pacjentami zakwalifikowanymi do kategorii B. 
Wnioski: Spektroskopia rezonansu magnetycznego nie po -
zwala na dok³adne rozpoznanie minimalnej encefalopatii
w¹trobowej. Podobny profil metabolitów w mózgu obserwuje
siê u pacjentów z marskoœci¹ w¹troby bez zaburzeñ poznaw-
czych. 
S³owa kluczowe: spektroskopia rezonansu magnetycznego,
minimalna encefalopatia w¹trobowa, marskoœæ w¹troby, ocena
neuropsychologiczna.
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The inclusion criteria for control subjects were: 1) lack
of history of neurological diseases; 2) normal result
of neurological examination; 3) normal result of MRI
of brain. The control group consisted of patients with
functional symptoms from the gastrointestinal tract
including patients with irritable bowel syndrome.
Neurological and neuropsychological examination
was performed in all participants. The neuropsycho-
logical assessment included the Trail Making Test
(TMT) part A and B, the Digit Symbol Test (DST)
and the Block Design Test (BDT) from the Wechsler
Adult Intelligence Scale Revised. These tests were cho-
sen because they have a high specificity for diagnosing
MHE and are recommended by the Working Party
commissioned by the World Congress of Gastroente -
rology [15,16]. MHE was defined as the result of one
or more tests below 2 standard deviations (SD) of the
mean obtained in the control group.
1HMRS was performed on a 1.5 T Magnetom So -
nata (Siemens) scanner with single voxel PRESS tech-
nique (TR = 1500 ms, TE = 30 ms, 256 acquisitions
with H2O signal suppression). Three voxels of 8 cm3
were positioned in the globus pallidus, predominantly
white matter in the frontal lobe, and predominantly gray
matter in the occipital cortex. Metabolite concentrations
were calculated manually, using integral Siemens soft-
ware. Peaks from Ins (position 3.54 ppm), Cho (posi-
tion 3.24 ppm) and N-acetyl-aspartate (NAA) (position
2.02 ppm) and Glx (integrated area under peaks 2.15,
2.23, 2.30 ppm) were normalized with respect to Cr
(position 3.04 and 3.93). According to the previous stud-
ies, it was assumed that creatine levels are not changed
in the course of hepatic encephalopathy.
MR was performed using the same machine (T1-
weight ed images: TR 4000 ms/TE 122 ms; T2-weight-
ed images: TR 390 ms/TE 7.7 ms; FLAIR: TR 
1000 ms/TE 121 ms). Brightness of basal ganglia was
determined visually on T1-weighted images and classi-
fied as normal or increased signal intensity of the globus
pallidus.
The study protocol was approved by the Bioethics
Committee of the Jagiellonian University and informed
consent was obtained from each participant. 
The χ2 test was used to compare proportions, Mann-
Whitney U-test to compare continuous variables bet -
ween two groups and Kruskal-Wallis test to compare
continuous variables between three groups. For corre-
lation analysis, Spearman’s rank correlation test was
used. P-values of less than 0.05 were considered to indi-
cate statistical significance. The calculations were per-
formed using the statistical package STATISTICA for
Windows, v.9.0 (StatSoft, Inc).
Results
Forty-six patients with liver cirrhosis without overt
encephalopathy and 45 control subjects were enrolled.
The causes of liver cirrhosis were: hepatitis B (11 pa -
tients) and hepatitis C (10 patients) infections, alcohol
abuse (6 patients), autoimmune hepatitis (16 patients),
non-alcoholic steatohepatitis (1 patient), primary scle-
rosing cholangitis (1 patient) and haemochromatosis 
(1 patient). According to the Child-Pugh scale of hepa -
tic insufficiency, 26 patients were classified as having
Child-Pugh A disease, 19 patients were classified as
Child-Pugh B, and 1 patient as Child-Pugh C.
Demographic and laboratory characteristics as well as
results of neuropsychological tests are shown in Table 1.
There was no significant difference in age, sex or edu-
cation between studied groups. Compared to controls,
the patients with liver cirrhosis had higher levels of
aminotransferases, alkaline phosphatase and gamma-
glutamyl transpeptidase in serum. Ammonia level in
serum did not differ significantly between groups. 
There was no significant difference in results of neu-
ropsychological tests between patients and control sub-
jects.
The spectra from the globus pallidus and occipital
cortex were obtained in all participants; spectra from
the frontal lobe were obtained in 39 patients and 38 con-
trols. The metabolite ratios are shown in Table 2 and
Table 3. First, the group of all patients (those without
abnormalities on neuropsychological examination and
those with MHE) was compared with the control
group. The patients with liver cirrhosis had a decreased
ratio of Ins/Cr in occipital gray matter and frontal white
matter (mean: 0.17 ± 0.05 vs. 0.20 ± 0.04, p = 0.01
and 0.15 ± 0.05 vs. 0.19 ± 0.04, p < 0.01, respective-
ly), decreased ratio of Cho/Cr in occipital gray matter
(mean: 0.32 ± 0.07 vs. 0.36 ± 0.08, p = 0.03) and
increased ratio of NAA/Cr in the globus pallidus (mean:
1.95 ± 0.32 vs. 1.83 ± 0.34, p = 0.04). When three
groups (patients without abnormalities on neuropsy-
chological examination, patients with MHE and con-
trol subjects) were compared, ANOVA analysis revealed
that patients with MHE had a significantly decreased
ratio of Cho/Cr in the occipital lobe compared with
the control group and patients with liver cirrhosis with-
out MHE had a decreased ratio of Ins/Cr in the frontal
Irena Cieæko-Michalska, Tomasz Dziedzic, Robert Banyœ, Magdalena Senderecka, Marek Binder, Miros³aw Wyczesany, Jakub Szewczyk, Jan Wójcik, Agnieszka S³owik, Tomasz Mach
Neurologia i Neurochirurgia Polska 2012; 46, 5 439
and occipital lobe compared with control subjects. Meta -
bolite ratios did not differ significantly between patients
with and without MHE, although there was a statisti-
cal trend (p = 0.08) toward a lower ratio of Cho/Cr in
the occipital lobe in patients with MHE.
Metabolite ratios did not differ significantly in pa -
tients with Child-Pugh A and those with Child-Pugh B
(Table 3).
In patients with liver cirrhosis there was no signifi-
cant linear correlation between serum ammonia level
and metabolite ratios. INR correlated significantly 
(p < 0.05) with Ins/Cr ratio in the globus pallidus 
(R = –0.33), occipital cortex (R = –0.38) and frontal
lobe (R = –0.44) as well as Cho/Cr ratio in the globus
pallidus (R = –0.31).
Bright basal ganglia were found in 4 patients. These
patients did not differ significantly in neuropsycholog-
ical tests from those with normal signal intensity of
the globus pallidus. Also biochemical parameters did
not differ significantly between these groups, with
the exception of cholinesterase activity, which was low-
er in patients with bright basal ganglia (mean: 8776 ±
2859 vs. 5479 ± 2085 U/L, p = 0.02). Patients with
bright basal ganglia had a decreased ratio of Cho/Cr and
Ins/Cr in the globus pallidus (mean: 0.56 ± 0.15 vs.
0.78 ± 0.15, p = 0.01 and 0.16 ± 0.08 vs. 0.26 ± 0.08,
p = 0.03) and a decreased ratio of Ins/Cr in the occipi -
tal cortex (0.11 ± 0.05 vs. 0.17 ± 0.05, p = 0.04). There
was also a statistical trend towards a lower ratio of Ins/Cr
in the frontal lobe (0.09 ± 0.07 vs. 0.16 ± 0.05, 
p = 0.08).
Discussion
In this study, metabolite ratios did not differ signi -
ficantly between patients with liver cirrhosis with and
without MHE. Previous studies measuring the metabo-
lites in brains of patients with MHE brought equivo-
Patients (N = 46) Controls (N = 45) P-value
Age [years], mean (SD) 39.8 (10.4) 40.3 (13.2) 0.90
Female, n (%) 23 (50.0) 23 (51.1) 0.76
Education [years], mean (SD) 13.8 (2.7) 13.9 (2.7) 0.73
Biochemical parameters
Bilirubin [mmol/L], mean (SD) [normal value: 0.0-17.1] 18.1 (15.2) 13.1 (7.1) 0.09
Aspartate transaminase [U/L], mean (SD) [normal value: 10-40] 59.1 (48.6) 25.7 (13.0) < 0.01
Alanine transaminase [U/L], mean (SD) [normal value: 10-41] 96.7 (120.8) 32.4 (22.4) < 0.01
Gamma-glutamyl transpeptidase [U/L], mean (SD) [normal value: 5.0-61.0] 186.4 (255.2) 34.1 (28.6) < 0.01
Cholinesterase [U/L], mean (SD) [normal value: 5320-12920] 8363 (2821) 9095 (2208) 0.24
Alkaline phosphatase [U/L], mean (SD) [normal value: 91-258] 231.3 (150.1) 147.5 (85.1) < 0.01
Albumin [g/L], mean (SD) [normal value: 35.0-50.0] 45.7 (3.9) 47.2 (4.4) 0.23
Ammonia [μg/dL], mean (SD) [normal value: 9-33] 37.6 (19.7) 22.2 (7.3) 0.66
Prothrombin [INR], mean (SD) [normal value: 0.9-1.2] 1.1 (0.2) 1.0 (0.1) 0.04
Urea [mmol/L], mean (SD) [normal value: 1.7-8.3] 5.1 (1.3) 5.0 (1.4) 0.66
Platelets [1 × 103/μL], mean (SD) [normal value: 125-340] 198 (80) 220 (56) 0.30
Neuropsychological tests
TMT-A [s], mean (SD) 29.1 (14.4) 27.9 (8.6) 0.47
TMT-B [s], mean (SD) 70.9 (40.1) 68.5 (36.2) 0.77
DST, mean (SD) 51.1 (12.1) 53.9 (12.0) 0.41
BDT, mean (SD) 31.5 (8.4) 32.9 (8.3) 0.52
Table 1. Demographic, laboratory and neuropsychological data of patients with liver cirrhosis and control group
SD – standard deviation; TMT – Trail Making Test; DST – Digit Symbol Test; BDT – Block Design Test
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cal results. Geissler et al. [8] found a decreased ratio
of Ins/Cr in gray and white matter and an increased ratio
of Glx/Cr in gray matter in 21 patients with MHE com-
pared to healthy volunteers. The same changes in brain
metabolites accompanied by a decreased ratio of Cho/Cr
in white matter were also observed in patients with liv-
er cirrhosis with normal results of psychometric tests.
Laubenberger et al. [9] observed a decreased ratio of
Ins/Cr in gray and white matter and an increased ratio
of glutamine/Cr in gray matter in 4 patients with MHE
compared to controls. In that study, no significant dif-
ference was found between Ins and glutamine concen-
trations of asymptomatic patients and those with MHE.
Singhal et al. [11] used two-dimensional MRS to de -
monstrate a decrease in Ins and Cho and an increase in
Glx in occipital and frontal lobes of patients with MHE
compared with healthy subjects. The same profile
of metabolites was also detected in the anterior cingu-
lated region [10]. Rovira [12] compared metabolite lev-
els in 7 patients with MHE and 16 patients with liver
cirrhosis without cognitive impairment. They found that
ratios of Ins/Cr +phospho-Cr in white matter were sig-
nificantly more decreased and ratios of Glx/Cr +phos-
pho-Cr were increased in cirrhotic patients with MHE
Patients with liver cirrhosis Patients with minimal Control group P-value Post-hoc 
without encephalopathy encephalopathy (group 3) comparisons
(group 1) (group 2)
Globus pallidus N = 39 N = 7 N = 45
NAA/Cr 1.94 (0.31) 1.99 (0.38) 1.83 (0.34) 0.12
Cho/Cr 0.75 (0.15) 0.78 (0.23) 0.75 (0.14) 0.51
Ins/Cr 0.24 (0.07) 0.28 (0.13) 0.26 (0.07) 0.09
Glx/Cr 0.85 (0.25) 0.99 (0.18) 0.93 (0.31) 0.20
Occipital lobe N = 39 N = 7 N = 45
NAA/Cr 1.06 (0.20) 1.11 (0.25) 1.12 (0.22) 0.34
Cho/Cr 0.33 (0.07) 0.27 (0.06) 0.36 (0.08) 0.02 group 3 > group 2
Ins/Cr 0.17 (0.05) 0.15 (0.07) 0.20 (0.04) 0.04 group 3 > group 1
Glx/Cr 1.01 (0.23) 0.86 (0.40) 1.05 (0.29) 0.48
Frontal lobe N = 34 N = 5 N = 38
NAA/Cr 1.17 (0.35) 0.91 (0.24) 1.04 (0.25) 0.11
Cho/Cr 0.45 (0.12) 0.42 (0.09) 0.47 (0.09) 0.53
Ins/Cr 0.15 (0.05) 0.16 (0.09) 0.19 (0.04) < 0.01 group 3 > group 1
Glx/Cr 1.07 (0.35) 1.12 (0.04) 1.23 (0.35) 0.24
Table 2. Metabolite ratios (mean [SD]) in patients with liver cirrhosis without encephalopathy, patients with minimal encephalopathy and control subjects
NAA – N-acetyl-aspartate; Cho – choline; Cr – creatine; Ins – myo-inositol, Glx –  glutamine/glutamate 
Child-Pugh A Child-Pugh B P-value
Globus pallidus N = 26 N = 19
NAA/Cr 1.91 (0.30) 2.00 (0.34) 0.43
Cho/Cr 0.79 (0.15) 0.72 (0.18) 0.40
Ins/Cr 0.25 (0.07) 0.24 (0.10) 0.60
Glx/Cr 0.87 (0.25) 0.87 (0.24) 0.91
Occipital lobe N = 26 N = 19
NAA/Cr 1.04 (0.21) 1.11 (0.20) 0.18
Cho/Cr 0.32 (0.07) 0.32 (0.07) 0.74
Ins/Cr 0.17 (0.04) 0.15 (0.06) 0.77
Glx/Cr 1.03 (0.25) 0.96 (0.25) 0.41
Frontal lobe N = 22 N = 16
NAA/Cr 1.14 (0.22) 1.14 (0.48) 0.32
Cho/Cr 0.48 (0.11) 0.42 (0.12) 0.13
Ins/Cr 0.16 (0.05) 0.14 (0.05) 0.50
Glx/Cr 1.07 (0.39) 1.07 (0.25) 0.99
Table 3. Metabolite ratios (mean [SD]) according to the Child-Pugh scale
NAA – N-acetyl-aspartate; Cho – choline; Cr – creatine; Ins – myo-inositol, Glx –  gluta-
mine/glutamate
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compared to those without MHE. In another study,
Weissenborn [13] compared MRS data obtained from
9 patients with liver cirrhosis and without cognitive dis-
turbances, 6 patients with MHE and 6 patients with
hepatic encephalopathy grade I. ANOVA analysis show -
ed a difference between these 3 groups in ratios of
Ins/Cr and Cho/Cr with the lowest value of these me -
tabolites in patients with MHE. There was also a sta-
tistical trend (p = 0.07) for an increased ratio of Glx/Cr,
with the highest value in patients with hepatic en -
cephalopathy. The changes in metabolite concentrations
were seen only in white matter. Although direct com-
parison of published studies is not possible due to dif-
ferences in study design (definition of MHE, MRS
acquisition and analysis protocols, etc.), some general
conclusions can be drawn. The cited studies demon-
strated that patients with MHE have decreased ratios
of Ins/Cr and Cho/Cr and an increased ratio of Glx/Cr
compared to healthy subjects. However, a similar pro-
file of metabolites could be seen in patients with liver
cirrhosis without cognitive disturbances. Our results
and the results of some previous reports [8,9] suggest
that there is no significant difference in metabolite ratios
between patients with MHE and patients with liver cir-
rhosis without cognitive impairment. In contrast, some
studies have shown quantitative differences between
patients with and without MHE [12,13]. Even in these
studies, there were significant overlaps in metabolite con-
centrations between patients with and without MHE.
Therefore, it seems that MRS is not helpful in differ-
entiation between these two groups of patients without
overt encephalopathy. 
MRS is a rapidly growing area of technological ad -
vances. In our study we measured only a limited num-
ber of metabolites. We cannot rule out the possibility
that changes in other metabolites, not studied by us,
could be important for differentiating patients with and
without MHE.
In this study patients with liver cirrhosis had a de -
creased ratio of Ins/Cr in occipital gray matter and
frontal white matter and a decreased ratio of Cho/Cr in
occipital gray matter. These results suggest that the
depletion of Ins is an early phenomenon that precedes
the increase in Glx. 
Some previous studies have suggested that the
changes in metabolite levels in the brain reflect
the chronic metabolic derangement associated with the
hepatic functional reserve [13,17]. The Ins level was
inversely correlated with the Child-Pugh score. Also
the Co level was lower and the Glx level was higher in
patients with Child-Pugh B/C than in patients with
Child-Pugh A. However, these data were obtained from
a group of patients with liver cirrhosis that also includ-
ed persons with overt hepatic encephalopathy. We did
not find differences in metabolite levels between patients
with Child-Pugh A and B. This may suggest that in
patients without overt encephalopathy who have a rela-
tively low serum ammonia level, factors other than
the degree of liver dysfunction determine metabolite
ratios in the brain.  
The presence of signal hyperintense basal ganglia in
T1-weighted images in patients with liver cirrhosis is
related to deposition of manganese [18]. We found that
patients with bright basal ganglia had lower ratios
of Ins/Cr in gray and white matter and a lower ratio
of Cho/Cr in basal ganglia. This may suggest that pal-
lidal hyperintensities are visible when Ins depletion
reaches a certain degree.
Conclusions
Our results suggest that MRS does not allow accu-
rate diagnosis of MHE, because a similar profile
of metabolites in the brain is observed in patients with
liver cirrhosis without cognitive impairment. To draw
firm conclusions regarding the utility of MRS in patients
with MHE, a larger group of patients is needed.
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